R&D Committee

Basic Policy

The R & D Committee investigates and reviews R&D-related issues necessary to enhance the drug discovery capabilities of pharmaceutical companies, resolves issues common to all JPMA members, and promotes activities to realize JPMA's Vision for 2035 and its Policy Recommendations. To this end, the committee makes proposals to government policies related to R&D in the fields of health, medicine, and life sciences, and in addition to the activities of the Drug Discovery Research Committee, Translational Research Committee, and Industry-Academia-Government Collaboration Committee, plans and promotes activities such as working groups through collaboration across committees and subcommittees that can respond flexibly and flexibly to changes in society and the environment. Plan activities of working groups, etc.・ Promote。

Priority Issues

  1. JPMA's Vision for 2035 and promotion of activities to realize the policy recommendations
  2. Follow-up and proposal of science, technology and innovation policies related to health, medicine and life science
  3. Development and strengthening of science and technology infrastructure related to drug discovery research
  4. Promotion of translational research
  5. Promote industry-academia-government collaboration for drug discovery innovation

Priority Tasks to be addressed

Initiatives -1

  1. Promotion of R & D Committee policies based on JPMA's policy recommendations and collaboration with other committees
  2. Study and promotion of measures to improve the environment for innovative drug discovery

Initiatives-2 (WG for Policy, WG for Promotion of Bioresource/Cohort Utilization, TF for Regulatory Reform, TF for Ethical Guidelines, TF for Brain Science Research Area)

  1. In collaboration with the Pharmaceutical Industrial Policy Committee, etc., make recommendations to and respond to policies related to the improvement of the research environment in the health/medical and life science fields
  2. Collaboration with relevant government ministries and agencies and related stakeholders to improve the environment for pharmaceutical research and development and to issue specific opinions

Initiatives-3 (Drug Discovery Research Subcommittee)

  1. Study and promotion of measures to apply new fundamental technologies to drug discovery research
  2. Recommendations for improvement of drug discovery research capabilities and environment

Initiatives-4 (Translational Research Subcommittee)

  1. Study and propose measures to revitalize and promote translational research
  2. Efforts to improve the environment for effective utilization of medical information and other utilization infrastructures

Initiatives-5 (Industry-Academia-Government Collaboration Subcommittee)

  1. Study and make recommendations on ways to strengthen and promote cooperation between industry, academia and government, and disseminate them
  2. Study, promotion, and recommendation on the activation of venues for drug discovery innovation

Related Information

Share this page

TOP

Site Search